Alcohol consumption and stroke: difficulties in assessing the relationships. by Britton, Annie et al.
Chenet, L; Britton, A (2001) Weekend binge drinking may he linked
to Monday peaks in cardiovascular deaths. BMJ (Clinical research
ed), 322 (7292). p. 998. ISSN 0959-8138
Downloaded from: http://researchonline.lshtm.ac.uk/17111/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/2.5/
Not reading and signing letters you have dictated is dangerous
Editor—For some time I have been
unhappy at the number of letters that I
receive unsigned, usually from fellow con›
sultants but more recently also from general
practitioners. After the warm best wishes at
the end of the letter they usually state
“Dictated but sent unsigned to avoid delay”;
as we both know, this is almost always totally
untrue.
I know many consultants who virtually
never sign their letters and, worryingly,
never read them after dictating them. To add
insult to injury, I recently saw a copy of a let›
ter from a consultant to a general prac›
titioner, unsigned and from the mistakes
obviously unread, in which he had the cheek
to encourage the general practitioner to
send patients for assessment at the private
hospital where he worked.
Last year I returned from having spent
one month in the United States; there was
an enormous amount of post awaiting my
attention, much of it medical. The final trig›
ger to my writing this letter was that of this
large number of letters (mostly from fellow
consultants but also from general practition›
ers) over half were unsigned and had that
dishonest explanation in lieu of a signature.
Several years ago I recall reading a letter in a
newspaper from a medical colleague
expressing concern about this matter, and
he neatly and precisely gave his view—which
I share—that the practice is both discourte›
ous and dangerous.
The discourtesy is of course regrettable,
but the dangerousness is of far greater
importance—not least now, when the public
image of doctors is so severely battered. I
can certainly confirm the dangerousness of
the practice but will give just two examples.
One letter from a consultant physician
ended with the warm greeting “with very
best wishes, yours very sincerely,” and
referred to a patient and her family
requiring my assessment concerning her
“antihypertensive treatment” whereas in fact
it should have said “antidepressive treat›
ment.” Another consultant’s letter referred
to a patient receiving chlorpromazine when
in fact she was being treated with clomi›
pramine; had he read the letter he would
have seen this error.
This matter must be aired, and to have
any impact I am sure that it requires a jour›
nal of the calibre of the BMJ for any useful
impact to be made.
Stanley Shere consultant psychiatrist
Woodley House, Nackington Road, Canterbury,
Kent CT4 7AX
PS. I have just received an unsigned letter from a
consultant informing me that he is treating the
patient with clonazepam in a dose of 500 mg daily; I
imagine that this dose would be lethal.
Hospital league tables
There are lies, damn lies, and hospital
statistics
Editor—Kmietowicz’s news article on hos›
pital league tables states that the biggest pre›
dictor of death rates was the number of
doctors in the hospital.1 This conclusion was
drawn by Professor Sir Brian Jarman and (in
the Sunday Times) underpinned by data from
Greenwich District Hospital.
Unfortunately for the conclusion, the
data are wrong. The Department of Health’s
figures for Greenwich seem to be for
consultants only and do not include junior
doctors. This introduces an error of an order
of magnitude between two and three. All
hospitals’ figures are likely to be distorted
further by the fact that staff in unrecognised
posts (often posts with strange titles such as
“trust doctors”) are not counted.
When such a fundamental and massive
data error passes unchecked and results in
false deductions, doubt is cast on the whole
process. We cannot blame Dr Foster Ltd,
which issued a disclaimer on data accuracy
in the small print, but in my view it is quite
wrong of the Department of Health to allow
publication without looking closely at
figures that departed so greatly from the
mean.
If garbage is put in, one gets garbage out.
A pity, really, because the idea is not bad.
Andrew Bamji consultant rheumatologist
Queen Mary’s Hospital, Sidcup, Kent DA14 6LT
Andrew_Bamji@compuserve.com
1 Kmietowicz Z. Hospital tables “should prompt authorities
to investigate.” BMJ 2001;322:127. (20 January.)
Analysis is flawed
Editor—The analysis by Dr Foster Ltd of
death rates in hospital trusts is so flawed that
the NHS should ignore it.1 Standardised
hospital mortality ratios are inappropriate
for this exercise and difficult to interpret.
They were originally public health measures
intended to apply to whole area populations
that are relatively static.
Patients admitted to a hospital do not
constitute a predefined population; this
population is arbitrary and depends heavily
on admissions policy and the availability of
support and other community services
locally. Furthermore, standardised mortality
ratios cannot be used to compare different
areal units.2
The report does not give managers and
clinical leaders any clue about how to
improve quality. Should they look for rogue
surgeons or killer nurses or shortcomings in
clinical care? If the latter, then what’s new?
We were doing that anyway.3 4 The study has
served only to divert managers in “bad” hos›
pitals into answering hysterical queries from
the press; to induce self righteous compla›
cency in “good” hospitals; and to encourage
lawyers to chase after every death, expected
or otherwise.
Patients don’t benefit either. How does
knowing a hospital’s mortality index help?
This index is a crude estimate of the a priori
average risk of dying while in hospital. Who
does it apply to? It applies only to statistically
“average” patients—an esoteric concept for
risk modelling enthusiasts, but of no help to
individual patients, who need an estimate of
their individual chances of a successful
outcome.
Nor can the analysis be improved.
Clever statistical manipulation of the dataset
cannot get us out of the mess resulting from
the inversion of the logical process of
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rational epidemiological analysis. The study
started with data that happened to be there;
then the researchers did some sophisticated
(and therefore seductively persuasive) analy›
sis, suggested a few answers (if you torture a
dataset enough it will confess to whatever
you want), and then asked “What possible
question is this the answer to?” It certainly
does not answer the question “Which hospi›
tals have poor quality care as judged by
mortality?”
Ideally we should start with the question,
refine it as far as possible, determine what
data we need to answer it with an acceptable
degree of validity, collect the relevant data,
and then analyse them. There are other and
better approaches to quality measurement.5
Blunderbuss analysis of a dataset collected
for administrative purposes is unhelpful.
Jammi N Rao deputy director of public health
Sandwell Health Authority, West Bromwich
B70 9LD
jammi.rao@sandwell›ha.wmids.nhs.uk
1 Kmietowicz Z. Hospital tables “should prompt authorities
to investigate.” BMJ 2001;322:127. (20 January.)
2 Court BV, Cheng KK. Pros and cons of standardised mor›
tality ratios. Lancet 1995;346:1432.
3 Department of Health. A first class service. Quality in the new
NHS. London: DoH, 1999.
4 Department of Health.An organisation with a memory: report
of an expert group on learning from adverse events in the NHS.
London: DoH, 2000.
5 Mohammed MA, Cheng KK, Rouse A, Marshall T. Bristol,
Shipman and clinical governance: Shewhart’s forgotten
lessons. Lancet 2001;357:463›6.
Opportunity may be more
important than profession in
serial homicide
Editor—Kinnell suggests that the incidence
of serial homicide among doctors may indi›
cate a pathological interest in the power of
life and death.1 He notes that other
professions may have fewer murderers. Our
analysis of serial killers in nursing suggests
an alternative interpretation.2
At least in relation to the murder of
patients, nursing provides further examples
of healthcare staff who have murdered
patients in their care. In a review of 34 serial
murderers in the United States, six were
nurses.3 We identified 13 convictions of
nurses for the serial murder of patients up to
1997.2 In Hickey’s series, nurses had often
killed for several years before they were
identified.3 Higher risk is associated with the
delivery of intravenous fluids, with being in a
bed out of sight of a nursing station, and
with evenings or nights.2
When this information is combined with
Kinnell’s observations on Shipman and
Nesset, it begins to seem plausible that all
walks of life have people with the potential
to murder. The key difference may be
opportunity. The features associated with
risk noted above suggest that access and a
low chance of observation are important.
The difference between nurses and doctors
may be that doctors also control the means
of disposal—in the case of Nesset and Ship›
man, they also provided the death certificate.
The reason for the difference in the number
of reported deaths may simply relate to the
doctors’ greater opportunity to remain
undiscovered.
The difference between professions may
be less striking than it first seems. We should
not focus on one occupation. It is more
important to develop safe systems. We have
argued for the importance of appropriate
critical incident review, which allows the
identification of serial murder as well as
other far commoner problems.4 Shipman’s
case should not promote paranoia but
should lead us to consider how best to iden›
tify problems. The techniques for further
analysis of unexpected deaths are readily
available, but we should not confine our
attention to any one possible cause or
profession.
Cameron Stark consultant in public health medicine




Department of Nursing, Stirling University, Stirling
FK9 4LA
Brian Kidd consultant psychiatrist
Forth Valley Primary Care NHS Trust, Royal
Scottish National Hospital, Larbert FK7 8AH
1 Kinnell K. Serial homicide by doctors: Shipman in
perspective. BMJ 2000;321:1594›7. (23›30 December.)
2 Stark C, Paterson B, Henderson T, Kidd B, Godwin M.
Counting the dead. Nursing Times 1997 93;46:34›7.
3 Hickey EW. Serial murderers and their victims. Pacific Grove,
CA: Brooks/Cole, 1991.
4 Stark C, Sloan D. Murder in the NHS: audit critical
incidents in patients at risk. BMJ 1994;308:477.
“Old age” should be not be
acceptable on death certificates
Editor—Dyer reports that a new agency to
catch underperforming or incompetent
doctors has been set up.1 It was set up in the
wake of an official report confirming that
Harold Shipman, a British general prac›
titioner serving life for killing 15 patients,
was one of the most prolific serial murderers
in history.
One of the diagnoses found to be
unusually common on death certificates for
deaths certified by Shipman was “old age.”
The rules in the front of books of death cer›
tificates allow this diagnosis to be used for
people aged over 70. But patients aged
70›75 are not classified as elderly today. Few
doctors who work with elderly people are
unable to give a specific cause of death, even
for patients over 95. I use “old age” only
for those few patients over 85 (no more
than one a year) who make an active
decision to fade away and in whom disease
has been excluded by physical examination,
blood tests, basic radiology, and psychiatric
examination.
The time has come to restrict or
even abolish use of this cause of death on
certificates.
Kalman Kafetz consultant physician, medicine for
elderly people
Whipps Cross Hospital, London E11 1NR
kalmankafetz@hotmail.com
1 Dyer C. New agency set up to identify incompetent
doctors. BMJ 2001;322:67. (13 January.)
Headache after diagnostic
lumbar puncture
Using 20 gauge needle is blunderbuss
technique
Editor—The results of Thomas et al’s trial
of atraumatic versus standard needles for
diagnostic lumbar puncture1 confirm those
of others on this topic,2–5 as well as my own
personal experience. As both gauge and
needle type matter,5 I am curious as to why
they did not use a finer needle, consistent
with most previous efforts to reduce spinal
headache.
Use of a 20 gauge needle improved the
study’s power by increasing the overall rate
of spinal headaches versus rates in other
studies,2–5 but it can hardly be recommended
as standard technique. The fact that one can
kill houseflies with a shotgun does not mean
that it is better to do so.
James S Smeltzer consultant, maternal fetal medicine
Wellstar Physicians’ Group, Northwest Women’s
Care, 787 Campbell Hill Street, Marietta, GA
30060, USA
James.Smeltzer@wellstar.org
1 Thomas SR, Jamieson DRS, Muir KW. Randomised
controlled trial of atraumatic versus standard needles for
diagnostic lumbar puncture. BMJ 2000;321:986›90. (21
October.)
2 Eriksson AL, Hallen B, Lagerkranser M, Persson E,
Skoldefors E. Whitacre or Quincke needles—does it really
matter? Acta Anaesthesiol Scand Suppl 1998;113:17›20.
3 Holst D, Mollmann M, Ebel C, Hausman R, Wendt M. In
vitro investigation of cerebrospinal fluid leakage after
dural puncture with various spinal needles. Anesth Analg
1998;87:1331›5.
4 Corbey MP, Bach AB, Lech K, Frorup AM. Grading of
severity of postdural puncture headache after 27›gauge
Quincke and Whitacre needles. Acta Anaesthesiol Scand
1997;41:779›84.
5 Morewood GH. A rational approach to the cause, preven›
tion and treatment of postdural puncture headache. Can
Med Assoc J 1993;149:1087›93.
Smaller is better where needles are
concerned
Editor—It is unfortunate that Thomas et al
devoted so much effort towards reducing
the risk of headache after lumbar puncture
from 50% to 28% by using an atraumatic
needle1 when a smaller needle would have
had a much more beneficial effect. In a line
or two they dismissed anaesthetic and radio›
logical practice, where atraumatic needles as
small as 24 gauge are routine and an
incidence of headache of < 10% after
lumbar puncture is expected.
A large meta›analysis, which included 12
studies from 1966 to 1993, found that the
incidence of headache after lumbar punc›
Odds ratios and confidence intervals in
meta›analysis looking at design of spinal needles
and headache after lumbar puncture2
Pooled
odds ratio 95% CI
Headache after lumbar puncture:
Non›cutting v cutting needle 0.26 0.11 to 0.62
Small v large needle 0.18 0.09 to 0.36
Failure:
Non›cutting v cutting needle 0.52 0.27 to 1.01*
Small v large needle NA 0.67 to 2.42*
NA=Not applicable. *Not significant.
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ture was significantly reduced by both the
use of smaller needles and the use of an
atraumatic point (table).2 The combined
odds ratios favoured the smaller needle. As a
measure of ease of use, there was no signifi›
cant difference in the failure rate with type of
point or needle size.
Anaesthetic trainees rapidly acquire a
facility with small, atraumatic spinal needles.
Cerebrospinal fluid may flow more slowly,
but what other reason is there not to do
diagnostic taps with a small atraumatic
spinal needle?
John R Davies consultant anaesthetist
Department of Anaesthesia, Lancaster Acute
Hospitals NHS Trust, Royal Lancaster Infirmary,
Lancaster LA1 4RP
john.r.davies@k.bay›tr.nwest.nhs.uk
1 Thomas SR, Jamieson DRS, Muir WM. Randomised
controlled trial of atraumatic versus standard needles for
lumbar puncture. BMJ 2000;321:986›90. (21 October.)
2 Halpern S, Preston R. Postdural puncture headache and
spinal needle design. Metaanalyses. Anesthesiology
1994;81:1376›83.
Authors should have used smaller gauge
needles
Editor—We wish to raise some issues about
Thomas et al’s trial of atraumatic versus
standard needles for diagnostic lumbar
puncture.1
Firstly, the principal objective of the
study was to see if use of 20 gauge
atraumatic spinal needles rather than 20
gauge standard needles reduced the inci›
dence of headache after lumbar puncture.
The authors stated that there had been only
two previous studies of this type that were
methodologically adequate; these were not
referenced.
Secondly, the authors stated that the
incidence of headache after spinal anaesthe›
sia is typically half that after diagnostic lum›
bar puncture. There is no evidence that that
is the case when needles of the same calibre
are used and when follow up is adequate.
The articles they referenced here do not
make that claim.
Thirdly, the authors chose to use 20
gauge needles; this needle size is associated
with a rate of headache after dural puncture
of up to 36.5%.2 The headache rate falls with
decreasing needle gauge. An article in 1956
described the use of 22 gauge needles,3 and
an editorial in the BMJ in 1997 recom›
mended the use of 22 gauge atraumatic nee›
dles for diagnostic lumbar puncture.4 One of
the authors’ references showed that the flow
rate of cerebral spinal fluid through a 22
gauge atraumatic needle was adequate. So
why are they still using large gauge needles
when this can lead to appreciable morbidity?
The outcome of this study was predict›
able. Greene first recommended the use of
atraumatic needles in 1926, and Whitacre
developed the needle in 1951. Many units
are now using 22 gauge atraumatic needles
for diagnostic lumbar puncture. Our unit
recently changed to using 22 gauge Whit›
acre needles; this change has seen a
reduction in headache after lumbar punc›
ture from 27% to 17% and has not been
associated with an increase in the average
number of attempts (1.6 with the standard
needle versus 1.4 with the Whitacre needle).
If the authors wish to put together a sys›
tematic randomised trial that shows a reduc›
tion in headache after diagnostic lumbar
puncture5 perhaps they should have consid›
ered using smaller gauge needles.
David Turnbull lecturer in anaesthesia
University of Sheffield, Sheffield S10 2RX
David.Turnbull@csuh.nhs.uk
Fiona McKevitt neurology research fellow
Royal Hallamshire Hospital, Sheffield S10 2JF
1 Thomas SR, Jamieson DRS, Muir KW. Randomised
controlled trial of atraumatic versus standard needles for
diagnostic lumbar puncture. BMJ 2000;321:986›90. (21
October.)
2 Kuntz KM, Kokemon E, Stevens JC, Muller P, Offord KP,
Ho MM. Post lumbar puncture headache: experience in
501 consecutive procedures. Neurology 1992;42:1884›7.
3 Vandam LD, Dripps RD. Long term follow up of patients
who received 10 098 spinal anesthetics. JAMA
1956;161:586›91.
4 Broadley SA, Fuller G. Lumbar puncture needn’t be a
headache. BMJ 1997;315:1324›5.
5 Sudlow C. Preventing headache after lumbar puncture:
Evidence must come from randomised trials put together
systematically. BMJ 1998;317:1589.
Author’s reply
Editor—These correspondents identify a
reduced incidence of headache after dural
puncture with smaller gauge needles. Their
citations in support of this testify to the ori›
gins of such data, which are almost
exclusively in anaesthesia. In neurological
practice, use of needles smaller than 20›22
gauge is rare since smaller needles prolong
the time taken to obtain the moderately
large volumes of cerebrospinal fluid and for
pressure measurement by manometry.
We certainly did not choose 20 gauge
needles to increase the power of our study;
we chose them because this represents rou›
tine practice. Reduction of headache after
dural puncture must be balanced against the
technical difficulty of the procedure, and use
of very small gauge needles may be subject
to the same increase in difficulty that we
showed for atraumatic needles. A recent
assessment under the auspices of the
American Academy of Neurology empha›
sises the limited evidence for adoption of
anaesthetic innovations for diagnostic lum›
bar puncture.1
Critics of neurologists and others per›
forming diagnostic lumbar punctures
should bear in mind that diagnostic lumbar
puncture is not identical with spinal
anaesthesia; extrapolation of anaesthetic
data without proper appraisal may not be
justified.
Keith W Muir consultant neurologist
Southern General Hospital, Glasgow G51 4TF
k.muir@clinmed.gla.ac.uk
1 Evans RW, Armon C, Frohman EM, Goodin DS.
Assessment: Prevention of post›lumbar puncture head›
aches. Report of the therapeutics and technology
assessment subcommittee of the American Academy of
Neurology. Neurology 2000;55:909›14.
Doctor given intrathecal methotrexate
had headache when 20 gauge standard
needle was used
Editor—In their editorial Serpell and Rawal
remind us that use of small atraumatic
needles can greatly reduce the incidence of
spinal headache after lumbar puncture.1 2
This is well known to anaesthetists; why not
to others?
Doctors’ “see one, do one, teach one”
mentality is largely to blame. As a medical
house officer I was taught to use 20 gauge
standard (Quincke) needles for lumbar
punctures, but as an anaesthetics senior
house officer I soon learnt that using 25
gauge atraumatic (Whitacre) needles makes
dural puncture and spinal anaesthesia
simple, quick, and effective.
Two years ago I had to receive regular
intrathecal methotrexate for non›Hodgkin’s
lymphoma. After my first session of chemo›
therapy, when a 20 gauge standard needle
was used for the intrathecal dose, I was bed›
bound for a week with backache and the
classic signs of a spinal headache. At my next
visit I tried in vain to explain to the consult›
ant that I had had a severe spinal headache,
and I asked for smaller atraumatic needles to
be used. I was told that this time I would be
given intrathecal steroid to counteract my
“arachnoiditis.” I was sceptical but, as a
disempowered patient, had to submit.
This time I was bedbound for two weeks.
Thereafter I refused intrathecal methotrex›
ate unless an anaesthetist performed the
procedure. As I expected, the anaesthetics
senior house officer or registrar was happy
to do this. Dismayed at the routine use of
large traumatic needles on the oncology day
unit, the anaesthetist also taught the
oncology senior house officer how to use 25
gauge Whitacre needles routinely.
As a patient with cancer, you accept that
some unpleasant side effects of treatment
are unavoidable. But spinal headaches often
arise from a simple lack of interest in and
understanding of prevention and treat›
ment.3 4 Incidentally, patients receiving
chemotherapy cannot receive blood patch›
ing because of the risk of infection and
thrombocytopenia. Many patients having
chemotherapy are young and therefore at
greatest risk of spinal headache. When
patients are having chemotherapy every
three weeks there is a small window between
recovery from treatment and the onset of
neutropenia when it is possible to feel well
and live a relatively normal life. This
precious time is lost when it is spent lying in
a dark room.
The use of small atraumatic needles
should become routine for all medical
specialties.
Susannah Baron specialist registrar in dermatology
Leeds General Infirmary, Leeds LS1 3EX
zannerzu@onetel.net.uk
1 Serpell MG, Rawal N. Headaches after diagnostic dural
punctures. BMJ 2000;321:973›4. (21 October.)
2 Thomas SR, Jamieson DRS, Muir KW. Randomised
controlled trial of atraumatic versus standard needles for
diagnostic lumbar puncture. BMJ 2000;321:986›90. (21
October.)
3 Serpell MG, Haldane GJ, Jamieson SR, Carson D. Preven›
tion of headache after lumbar puncture: questionnaire
survey of neurologists and neurosurgeons in United King›
dom. BMJ 1998;316:1709›10.
4 Sharma A. Preventing headache after lumbar puncture:
most doctors are unaware of features of headache after
lumbar puncture. BMJ 1998;317:1588.
Letters




postgraduate training may raise awareness
Editor—Globalisation, as mentioned in the
article by Lee and Mills,1 is gaining
increasing relevance to medical practice in
the developed and developing world. But it
is an issue barely covered in undergraduate
medical curriculums. British medical stu›
dents, through the Medical Students’ Inter›
national Network (www.medsin.org), are
trying to redress this balance by increasing
the awareness of humanitarian issues and
inequalities in health locally and globally.
Through community based projects—for
example, working with local asylum
seekers—students are introduced to the
concept that global health begins on their
doorstep. Through collaboration with inter›
national counterpart organisations, medical
students can learn the true nature of the dis›
eases affecting large proportions of human›
ity, which, as Lee and Mills describe, are
given little global attention. The medical stu›
dents of today are the global health
practitioners of the future. If these practi›
tioners are to be effective in targeting the
disease burden of the world’s poorest they
must first be made aware of its presence
during their undergraduate education.
If the partnership models of research
into the developing world, such as those
suggested by Costello and Zumla,2 are to be
widely implemented, the participation of
doctors in the West must be encouraged
through greater flexibility in their under›
graduate and postgraduate training.
Sarah Finer fourth year medical student
Royal Free and University College Medical School,
London WC1E 6BT
s.finer@ucl.ac.uk
1 Lee K, Mills A. Strengthening governance for global health
research. BMJ 2000;321:775›6 (30 September.)
2 Costello A, Zumla A. Moving to research partnerships
in developing countries. BMJ 2000;321:827›9. (30
September.)
Ways of getting vitamin A to children in
developing countries have to be improved
Editor—Lee and Mills in their article have
raised crucial questions about drug related
medical research.1 Much research supports
an agenda determined by industrialised
nations. Diseases of tropical countries are
often neglected. Even where appropriate
diseases are investigated and results are epi›
demiologically unassailable, the nature of
the research and the application of findings
can undermine efforts of resource poor
countries to deal with the primary problem.
A study that elucidates biochemistry
does not always provide a solution.
Researchers suggest that children under six
months be given vitamin A supplements.2
Giving capsules to children to resolve
dietary deficiencies tells their families the
problem is beyond their control. It creates a
net capital flow out of poor countries when
the issue is those countries’ lack of economic
power.
Roche funds Sight and Life, a humani›
tarian initiative to combat vitamin A
deficiency with $23m (£16.1m) donated
between 1986 and 1999. To further this
work, the Sight and Life Research Institute
was established in 1998 with the Johns Hop›
kins School of Public Health.
In 1999 Roche, with 40% of the vitamin
market, was found to be the leader of “Vita›
mins Inc,” a conspiracy to set vitamin prices.
The head of the antitrust division of the
United States Justice Department described
this as the most pervasive and harmful anti›
trust conspiracy ever.3 Roche, BASF, Rhone›
Poulenc, and Takeda Chemical Industries
were involved, paying nearly $1 billion in
criminal fines, the biggest settlement in
American history.3 A Roche executive was
sentenced to five months jail. Further penal›
ties are likely in Europe and Canada. The
group made billions of dollars, more than it
will ever repay.3
These companies and three others have
agreed to settle a related class action for
$242m.4 Altogether 224 companies (which
provided 75% of the vitamins purchased)
have withdrawn from this suit to reach larger
individual settlements. One antitrust lawyer
working on the case stated there was no rea›
son to think that it would not happen again.3
In 1976 Roche was fined DM1 098 000
(£350 000) for similar activities.5
Vitamin A is important to childhood
development, but it is time to rethink the
best ways of getting it to children in poorer
countries. Supplementation takes pressure
off the search for a sustainable solution. The
best way for children to get vitamin A is
through their food. It is not naive to imagine
that this should be the foundation and end
point of all research into vitamin A
deficiency in children.
Jim Black national health and Medical Research
Council scholar
jim.black@med.monash.edu.au
Bebe Loff senior lecturer
Department of Epidemiology and Preventive
Medicine, Monash Medical School, Alfred Hospital,
Prahran, VIC 3181, Australia
1 Lee K, Mills A. Strengthening governance for global health
research. BMJ 2000;321:775›6 (30 September.)
2 Humphrey JH, Rice AL. Vitamin A supplementation for
young infants. Lancet 2000;356:422›4.
3 Barboza D. Tearing down the façade of “Vitamins Inc.”New
York Times 1999 Oct 10.
4 Anonymous. Settlement in vitamin case is approved. New
York Times 2000 Mar 13.
5 Adams S. Roche versus Adams. London: Jonathan Cape,
1984.
Ranitidine and gastrointestinal
bleeding in intensive care
Should prophylaxis against stress ulcer be
abandoned for patients in intensive care?
Editor—The meta›analysis of Messori et al
clearly confirms the lack of usefulness of sys›
tematic prophylaxis against stress ulcer with
H2 receptor antagonists or sucralfate,
1 but an
important issue is left unanswered by this
study and by the meta›analysis of Cook et
al.2 Indeed, some critically ill patients receive
prophylaxis against stress ulcers for specific
reasons, including brain injury (trauma, sur›
gery, haemorrhage), steroid treatment, and
coagulation abnormalities.
Does the available literature support
such prophylaxis for these patients? In other
words, should intensivists prescribe stress
ulcer prophylaxis for selected subgroups of
patients? If the available literature does not
resolve this issue, should the further trials
suggested by Messori et al stratify the groups
according to the patient’s condition?
Jean›Charles Preiser clinical director
Clinique Reine Fabiola, 73 avenue du Centenaire,
B6061 Montignies›sur›Sambre, Belgium
preiserj@ulb.ac.be
1 Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A.
Bleeding and pneumonia in intensive care patients given
ranitidine and sucralfate for prevention of stress ulcer:
meta›analysis of randomised controlled trials. BMJ
2000;321:1103›6. (4 November.)
2 Cook D, Reeve BK, Guyatt GH, Heyland DK, Griffith LE,
Buckingham L, et al. Stress ulcer prophylaxis in critically ill
patients: resolving discordant meta›analyses. JAMA
1996;275:308›14.
Occult blood loss is clinically important
Editor—Intensive care has always been a
difficult area for research.
Firstly, patients are rarely able to give
informed consent, which places increased
pressure on researchers and ethics commit›
tees to ensure patients are not exposed to
risk. This makes placebo controlled trials
difficult even when the standard treatment
has no good evidence for effect.
Secondly, the patient population is vari›
able and often small in number, which
makes comparison and recruitment of suffi›
cient numbers for statistical analysis difficult.
This is borne out by the meta›analysis by
Messori et al, in which meta›analysis B
assessing the effectiveness of sucralfate con›
sisted of one paper.1
We also have problems with the out›
come used in meta›analysis A, comparing
ranitidine with placebo. In four out of five
papers the outcome was acute, rapid blood
loss as seen by melaena, red blood through a
nasogastric tube, or haemodynamic
changes. These are the signs of an acutely
bleeding vessel in an ulcer, as is often seen in
patients presenting to accident and emer›
gency with haematemesis. The usual pathol›
ogy in intensive treatment units is different,
with the presence of multiple small ulcers,
stress ulcers, causing continual, low grade
blood loss, breakdown of mucosal defences,
and increased need for transfusion. Few of
these ulcers go on to erode gastric vessels
and cause dramatic blood loss. However,
75›100% of patients with critical illness
develop these within three days of being
admitted to intensive treatment units, even
in the absence of low perfusion states.2 We
dispute the implication from the paper by
Messori et al that this occult blood loss is not
clinically important. A paper by Burgess et al
suggested a benefit with ranitidine.3
The argument for prophylaxis against
stress ulcer has now moved on from
sucralfate with the renewed emphasis on
early enteral feeding, including the instilla›
tion of enteral feed at a low rate even in
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patients with high nasogastric aspirates and
ileus.4
Finally, there is the issue of prevention of
aspiration by using pharmacological agents.
Endotracheal intubation or tracheostomy
are not absolute guardians of the airway, and
leakage of material past the balloon of the
airway device is a real risk, in both intensive
care and anaesthesia. Ranitidine has been
shown to reduce gastric acidity during peri›
ods of high risk, and its use should still be
considered in the intensive treatment unit
during manipulation of the airway. Overall,
it is our practice to use stress ulcer
prophylaxis in all patients having intensive
treatment; the agent will depend on the
individual patient. We find it difficult to criti›
cise any of our colleagues’ choices in this
contentious area.
Tim Dexter consultant anaesthetist
Stephen Drage specialist registrar in anaesthetics
drage@clara.net
Wycombe Hospital, Wycombe HP11 2TT
1 Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A.
Bleeding and pneumonia in intensive care patients given
ranitidine and sucralfate for prevention of stress ulcer:
meta›analysis of randomised controlled trials. BMJ
2000;321:1103›6. (4 November.)
2 Shuman RB, Schuster DP, Zuckerman GR. Prophylactic
therapy for stress ulcer bleeding: a reappraisal. Ann Intern
Med 1987;106:562›7.
3 Burgess P, Larson GM, Davidson P, Brown M, Metz CA.
Effect of ranitidine on intragastric pH and stress related
upper gastrointestinal bleeding in patients with severe
head injury. Dig Dis Sci 1995;40:645›50.
4 Pingleton SK, Hadzima SK. Enteral alimentation and
gastrointestinal bleeding in mechanically ventilated
patients. Crit Care Med 1983;11:13›6.
Glycated haemoglobin,
diabetes, and mortality in men
Maybe disturbance in physiological
mechanisms regulating blood glucose is
risk factor for cardiovascular death
Editor—Khaw et al contribute to the
substantial literature showing an association
between measures of glycaemia and subse›
quent morbidity and mortality.1 They sug›
gest that “preventive efforts need to consider
not just those with established diabetes but
whether it is possible to reduce the
population distribution of HbA1c [glycated
haemoglobin].” This implies that the deter›
minant is the degree of hyperglycaemia.
In the non›diabetic population, glycated
haemoglobin principally reflects the fasting
blood glucose concentration, which has
been shown by several groups to predict
morbidity and mortality. One of these
groups, the DECODE (diabetes epidemiol›
ogy: collaborative analysis of diagnostic
criteria in Europe) Study Group, also
measured the blood glucose concentration
two hours after a load and found that
fasting concentrations were not additionally
predictive within two hour blood glucose
categories.2
In a cross sectional study with carotid
intima media thickness as a marker of
atherosclerosis, blood glucose concentra›
tions after a load (in particular the two hour
value) and incremental values (that is, above
fasting) were more strongly related to intima
media thickness than were fasting glucose or
glycated haemoglobin concentrations.3 Fur›
thermore, in a population based study in
Italy instability of fasting blood glucose con›
centrations over the years of observation was
an independent predictor of cardiovascular
mortality.4
Clearly there are several possible inter›
pretations of these findings. One is that it is
not glycaemia itself that is the risk factor but
the disturbance(s) in the physiological
mechanisms that regulate the blood glucose
concentration. This explanation would
agree with the disappointing results of
hypoglycaemic treatment in type 2 diabetes,
commented on by Barrett›Connor and
Wingard.5
R J Jarrett emeritus professor of clinical epidemiology,
University of London
45 Bishopsthorpe Road, London SE26 4PA
1 Khaw KT, Wareham N, Luben R, Bingham S, Oakes S,
Welch A, et al. Glycated haemoglobin, diabetes, and
mortality in men in Norfolk cohort of European prospec›
tive investigation of cancer and nutrition (EPIC›Norfolk).
BMJ 2001;322:15›8. (6 January.)
2 DECODE Study Group. Glucose tolerance and mortality:
comparison of WHO and American Diabetes Association
diagnostic criteria. Lancet 1999;354:617›21.
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glucose and glycemic spikes are more strongly associated
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de Marco R. Long›term instability of fasting plasma
glucose, a novel predictor of cardiovascular mortality in
elderly patients with non›insulin›dependent diabetes mel›
litus: the Verona diabetes study. Circulation
1997;96:1750›4.
5 Barrett›Connor E, Wingard DL. “Normal” blood glucose
and coronary risk. BMJ 2001;322:5›6. (6 January.)
Analytical information is required for
generalisation of data
Editor—Analytical information is required
before data can be generalised. Khaw et al’s
data suggesting that the relation between
cardiovascular disease and glycaemia is a
continuum extending throughout the non›
diabetic population are fascinating.1 Unfor›
tunately, as the paper stands, the results are
not generalisable since neither the method›
ology for assessing glycated haemoglobin
nor calibration data have been included.
Professional organisations throughout
the United Kingdom agree that percentage
glycated haemoglobin concentration should
be harmonised in relation to a common
standard2 and that, in the absence of a
primary calibrant, this standard should be
that used in the diabetes control and
complications trial.3 Without this infor›
mation, the results of the present study can›
not be compared against others; it is
inappropriate to discuss “a threshold com›
monly accepted for diagnosis of diabetes.’’
With an ion exchange method (HA›
8140, Menarini Diagnostics) widely used in
Europe the upper limit of the reference
range observed in non›diabetic subjects has
been reported as 5.1%4—equivalent to 5.9%
after standardisation as in the diabetes
control and complications trial. If either of
these cut off values was applicable to the
present study a large (although vastly differ›
ent) number of subjects in the study could
not be considered to have normal glycaemic
control. This could be explicable in terms of
the age range of the cohort (45›79 years)
and the association of increased age and
decreased glucose tolerance.5
The suggestion that a large percentage
of the cohort might have abnormal glycae›
mic control would not be surprising: Harris
et al, for example, showed that 27.1% and
42.9% of the male population of the United
States aged 55›64 and 65›74 respectively
had either impaired glucose tolerance or
diabetes.5 The present data could therefore
be explained on the basis that many patients
with impaired glucose tolerance were
included in the upper two thirds of the non›
diabetic population and that these patients
have an increased rate of cardiovascular
disease.
The authors should be encouraged to
provide at least a non›diabetic reference
range for their assay and preferably some
data relating their results to a method
aligned to the diabetes control and compli›
cations trial. This study can then be
compared with other work in this area.
Finally, the authors state that “HbA1c
[glycated haemoglobin] may provide a prac›
tical screening tool for diabetes or impaired
glucose tolerance.” Although this statement
could be true, the authors do not provide
any evidence to support it. The World
Health Organization has categorically stated
that glycated haemoglobin concentration
should not be used to establish the diagnosis
of diabetes, and this has been reiterated by
Diabetes UK.
Edmund Lamb consultant clinical biochemist
East Kent Hospitals NHS Trust, Kent and
Canterbury Hospitals, Canterbury CT1 3NG
edmund.lamb@kch›tr.sthames.nhs.uk
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BMJ 2001;322:15›8. (6 January.)
2 Marshall SM, Barth JH. Standardization of HbA1c
measurements—a consensus statement. Diabetic Med
2000;17:5›6.
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Authors’ reply
Editor—Jarrett suggests that it is not
glycaemia itself that is a risk factor but
disturbances in the physiological mecha›
nisms that regulate the blood glucose
concentration. The point of our analysis was
to examine the predictive value of glycated
haemoglobin measures for the risk of death
and the shape of the risk curve. In this
cohort, glycated haemoglobin predicted risk
of death continuously across the whole
population distribution.
Most of the excess events associated with
raised glycated haemoglobin concentrations
occurred at values below those that would be
used to define diabetes. Indeed, in the
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diabetes control and complications trial
there was no glycaemic threshold for the
development of long term complications; as
the glycated haemoglobin concentration
was reduced below 8% there were continu›
ing relative reductions in the risk of compli›
cations such as microalbuminuria and
retinopathy.1 In the United Kingdom pro›
spective diabetes study, strict control of
blood glucose reduced microvascular com›
plications significantly by 25%, but the study
had inadequate power to detect a smaller
difference (10%) in mortality related to
diabetes.2
In response to Lamb, we would point
out that full details of the assays, though
omitted from our paper in the printed jour›
nal, are given in the longer version of the
paper on the BMJ website (www.bmj.com/
cgi/content/full/322/7277/15). As stated in
that longer paper, the glycated haemoglobin
measurements were made in a single
laboratory using high performance liquid
chromatography on a Biorad Diomat. This
is a diabetes control and complications trial
standardised method.
The World Health Organization and
Diabetes UK may well have categorically
stated that glycated haemoglobin should not
be used to establish the diagnosis of
diabetes. We would hope, though, that such
consensus statements are based on evidence
rather than opinion and may be reconsid›
ered in the light of new evidence from stud›
ies such as ours about the nature of the
relation between glycated haemoglobin
concentration and risk of future events.
Of course we accept that there may be
other reasons not to use measurements of
glycated haemoglobin, such as the prob›
lems of standardisation between methods
and the limited availability of the test in less
developed parts of the world. However,
both these technical issues could be
rectified. There are no fundamental
obstacles to using glycated haemoglobin
concentration as a predictor of macrovascu›
lar complications and risk of death associ›
ated with hyperglycaemia.
Kay›Tee Khaw professor of clinical gerontology
kk101@medschl.cam.ac.uk
Nick Wareham Medical Research Council clinician
scientist
Institute of Public Health, University of Cambridge,
Addenbrooke’s Hospital, Cambridge CB2 2QQ
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2 UK Prospective Diabetes Study Group. Intensive blood
glucose control with sulphonylureas or insulin compared
with conventional treatment and risk of complications in
patients with type 2 diabetes (UKPDS 33). Lancet
1998;352:837›53.
Medicine is now using diagnostic criteria
rather than reference ranges
Editor—Khaw et al’s study showed that gly›
cated haemoglobin concentration is associ›
ated with mortality in men without diabetes.1
It is another illustration of the general rule
for a continuous variable: subjects with char›
acteristics outside the normal range have an
increased incidence of acute and chronic
conditions and higher mortality, and sub›
jects with normal characteristics do not have
equal mortality—in most cases the lowest
mortality is not close to mean values.2
This rule is true for many variables, from
height and weight to glycated haemoglobin
concentration. It is true for population sam›
ples and for very healthy subjects.3 For most
diseases the shape of the curve describing
incidence against the variable is individual
to that disease. For example, the curve of
cancer mortality versus blood cholesterol
concentration is different from that of
cardiovascular mortality versus blood chol›
esterol concentration.4 Every curve can be
explained if we try hard enough.
Medicine is drifting from using refer›
ence ranges to using diagnostic criteria. This
means that the diagnostic threshold is based
not on the distribution of values in healthy
subjects but on the trade›off between getting
false negative and false positive results.5 Cur›
rent diagnostic criteria for diabetes trade off
the probability of complications. Already
there is a tendency for people with blood
glucose concentrations in the normal range
(but with impaired tolerance) to receive
interventions; now comes the proposal to
involve the whole population.
The situation is similar for the diagnosis
of obesity: interventions are now given to
people with a body weight indicating not
obesity but overweight, and the population
is under pressure to reduce weight. Khaw et
al are wrong in stating that “it is uncertain
whether the relation between blood glucose
concentration and . . . diseases has a thresh›
old or is a continuum.” A threshold makes
for a simplified decision rule; a blurred bor›
der between healthy subjects and people
who are sick or at risk makes simple
explanation hard, but it is reality.
Medicine is historically limited to more
or less definite groups of people (those who
are “diseased”). The alternative is a medicali›
sation of traits, habits, and risks. This expan›
sion to the whole population arises because
only a small proportion of subjects at risk is
in the group above the diagnostic threshold;
it is a simple consequence of the low
effectiveness of the diagnosis. Indiscriminate
interventions are usually inefficient.
Vasiliy Vlassov professor
Saratov State Medical University, PO Box 1528,
Saratov, 410601 Russia
vvvla@sgu.ru
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Catheterisation in elderly
women is no “easy” option
Editor—In their review of the management
of urinary incontinence in women, Thakar
and Stanton say that patients with chronic
urinary incontinence, particularly elderly
patients, may be easier to manage with a
permanent indwelling catheter.1 As one of
the “geriatric giants” described by Isaacs in
1992, urinary incontinence is a serious
problem in older patients, with a prevalence
of one in five to 10 in women older than 65
years, rising to two in three in residents of
nursing homes.2 3 These patients deserve the
same attention and assessment as their
younger counterparts, even if they have
medical conditions that preclude appropri›
ate surgical treatment, or cognitive impair›
ment that prevents them from complying
with pelvic floor exercises or bladder
retraining.
Simple measures can often noticeably
improve symptoms. These might include
switching to decaffeinated tea or coffee,
excluding urinary tract infections or causes
of polyuria such as diabetes mellitus or
hypercalcaemia, reviewing drug treatment,
including the use of diuretics and drugs that
predispose to urinary retention, and practi›
cal measures to ensure that those with
physical disabilities have easy access to
toileting facilities. Cognitively impaired
patients may benefit from timed, prompted
voiding. Liaison with the continence nurse
adviser may help with the provision of aids
that make management of continence
acceptable to carers.
Long term urinary catheterisation
causes inevitable bacteriuria, which is diffi›
cult to eradicate and increases the risk of
pyelonephritis, bacteraemia, and sepsis. It is
an invasive procedure with an appreciable
morbidity and mortality,4 a fact that should
be taken into consideration before applying
it to frail elderly patients. In addition, in a
condition with such a high prevalence, wide›
spread use of long term urinary catheters
for incontinence has important cost implica›
tions, with the cost of medical consequences
of catheterisation outweighing the savings in
continence devices.5 Long term urinary
catheterisation should be considered only in
women with urinary retention for whom
intermittent self catheterisation is not
appropriate, and as a last resort in patients
in patients with excoriated skin or pressure
sores in whom other measures have failed.
Virginia Aylett specialist registrar
gin_aylett@yahoo.com
Olwyn Lynch specialist registrar
Department of Medicine for the Elderly, St James’s
University Hospital, Leeds LS7 9TF
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Weekend binge drinking may
be linked to Monday peaks in
cardiovascular deaths
Editor—As Martyn notes in an editorial, the
Monday peak in cardiovascular mortality
and morbidity has been documented in
various settings.1 We would like to develop
further the notion that alcohol consumption
is at least partly responsible. In countries
with known weekend binge drinking the
Monday peak is pronounced and is accom›
panied by slight increases in mortality on
Saturdays and Sundays. This has been
shown in countries of the former Soviet
Union2 and in Scotland.3
The epidemiological evidence on high
alcohol consumption and cardiovascular
mortality supports this hypothesis. Studies
that look at the pattern of drinking, either
directly or indirectly, have consistently found
an increased risk of cardiovascular death
(particularly sudden death) with binge
drinking.4
Physiological studies have also shown
that the effects of regular moderate drinking
versus binge drinking differ greatly.5 In binge
drinkers, cardioprotective changes in high
density lipoproteins are not seen and
adverse changes in low density lipoproteins
are acquired. Binge drinking seems capable
of predisposing the heart to arrhythmia,
both by reducing the threshold for ventricu›
lar fibrillation and by causing scarring of the
myocardium.
The myocardium may be especially sen›
sitive during withdrawal, as will occur after
weekend binges. In addition, irregular drink›
ing is associated with an increased risk of
thrombosis, which is most likely to occur
after heavy drinking stops. These physiologi›
cal mechanisms may explain the observed
increase in cardiovascular events during the
weekend and on Mondays.
We hypothesise that alcohol, particularly
when drunk in binges, acts as a catalyst on
acute ischaemic heart diseases, possibly
by being synergetic to other triggering
factors.
Laurent Chenet lecturer
European Centre on Health of Societies in
Transition, London School of Hygiene and
Tropical Medicine, London WC1E 7HT
laurent.chenet@lshtm.ac.uk
Annie Britton lecturer
Health Promotion Research Unit, London School
of Hygiene and Tropical Medicine
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Fillers can transform people’s
lives
Editor—Not only can fillers be educational,
as Singh points out,1 but they have the power
to transform people’s lives.
In his filler, entitled “Thank you for end›
ing 40 years of misery,” Lakhani described
his memorable patient, an 85 year old
woman whose life had been made “sheer
hell” by diarrhoea up to six times a day since
she had had a vagotomy and gastroenteros›
tomy in 1957, which had proved resistant to
treatment with a fat free diet, pancreatic sup›
plements, antibiotics, and codeine.2 Suspect›
ing this might be diarrhoea after vagotomy,
he treated her with the bile acid sequestrant
cholestyramine, which promptly restored
her bowel function to normal.
After describing this case in my weekly
medical column in the Sunday Telegraph nine
readers reported a similar dramatic
response after the initiation of cholesty›
ramine treatment. Two readers said that they
had had 26 years of “wind and fluid” and 31
years of “severe diarrhoea” after vagotomy
and two three years of “severe painful
diarrhoea” and diarrhoea for “several years”
after cholecystectomy. Two readers with irri›
table bowel syndrome reported having had
“many years” of severe diarrhoea and having
had diarrhoea “six times a day.” Three read›
ers with diverticulitis said that they had had
diarrhoea “every few days and without
warning,” colicky pains and diarrhoea “as
soon as I eat anything,” and “very bad
diarrhoea.”
Cholestyramine is a well recognised (if
probably underused) treatment for chronic
diarrhoea due to bile acid malabsorption as
may occur after abdominal surgery or in
association with inflammatory bowel dis›
ease. Its value in chronic idiopathic
diarrhoea—often attributed, as in this series,
to irritable bowel syndrome or divert›
iculitis—is more contentious, with conflicting
evidence as to the contributory role or bile
acid malabsorption (or increased endog›
enous bile acid secretion) and responsive›
ness to bile acid sequestrants.3 4
It might be more useful, in the absence
of a clear understanding of the pathophysi›
ological mechanisms involved, to take an
empirical view. Cholestyramine is prescribed
as an antidiarrhoeal agent in several
conditions, while 40% of those taking the
drug in a primary prevention trial for
coronary heart disease reported constipa›
tion as a side effect.5
Before patients with chronic diarrhoea
are diagnosed as having diverticulitis or irri›
table bowel syndrome, they should first be
given a therapeutic trial of cholestyramine.
Those experiencing a marked symptomatic
improvement could then be described as
having cholestyramine responsive diar›
rhoea. This would have the merit, certainly
for patients, of making doctors more aware
of this remarkably effective, if poorly
understood, remedy for a most debilitating
condition.
James Le Fanu retainer general practioner
Mawbey Brough Health Centre, London SW8 2UD
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Invalid health information is
potentially lethal
Editor—A picture of the cover of Benjamin
Spock’s record breaking bestseller Baby and
Child Care was used to illustrate a point Fer›
guson made in the section of his article sub›
titled, “From Dr Spock to drkoop.com.”1 We
are told that a Harvard pioneer in
cybermedicine—Warner Slack—has com›
pared the rapid growth of online health
resources to the seismic impact of the publi›
cation of Spock’s book, which, he suggested,
had rapidly made it clear that well informed
parents could take much better care of their
kids.
By coincidence, I had used the same pic›
ture of the cover of Spock’s book in the pre›
vious week at the Cochrane Colloquium in
Cape Town, but to make a different point. In
the edition of Baby and Child Care that I
bought as a recent medical graduate in the
mid›1960s, I had marked a passage which
read: “There are two disadvantages to a
baby’s sleeping on his back. If he vomits, he’s
more likely to choke on the vomitus. Also he
tends to keep his head turned towards the
same side . . . this may flatten the side of his
head . . . I think it is preferable to accustom a
baby to sleeping on his stomach from the
start.” No doubt like millions of his other
readers, I passed on and acted on this
apparently rational and authoritative advice.
We now know that the advice promul›
gated so successfully in Spock’s book led to
thousands, if not tens of thousands, of avoid›
able cot deaths. This should be a sobering
warning to those who exploit the internet to
promulgate health advice without ensuring
that reliable empirical research evidence has
shown that their prescriptions and proscrip›
tions are more likely to help than to harm
other people.
Iain Chalmers director
UK Cochrane Centre, Oxford OX2 7LG
ichalmers@cochrane.co.uk
1 Ferguson T. Online patient›helpers and physicians
working together: a new partnership for high quality
health care. BMJ 2000;321:1129›32. (4 November.)
Correspondence submitted electronically
is available on our website
Letters
998 BMJ VOLUME 322 21 APRIL 2001 bmj.com
